The use of monoclonal antibodies to target functionally important cell-surface proteins on bone-resorbing osteoclasts represents a promising approach for treatment of cancer-associated bone loss and other skeletal pathologies.
We identified Siglec-15, a little-studied sialic acid-binding receptor, as a candidate target that is highly upregulated during osteoclast differentiation induced by the cytokine RANKL.